Overview

  • Product nameAnti-FGFR1 antibody [M19B2]
    See all FGFR1 primary antibodies
  • Description
    Mouse monoclonal [M19B2] to FGFR1
  • SpecificityReacts with both alpha and beta isoforms.
  • Tested applicationsSuitable for: IHC-FoFr, ICC/IF, IP, WB, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant human ectodomain of FGFr1b expressed in E. coli beginning with proline 23; antigen contained NH2-terminal gly-ser-pro-gly-ile and COOH-terminal glu-phe sequences.

  • EpitopeEpitope is within the NH2-terminus of Ig loop II sequence lys145 and glu159 between the acidic box and heparin-binding sequence of FGFr1.

Properties

Applications

Our Abpromise guarantee covers the use of ab823 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-FoFr Use at an assay dependent concentration. PubMed: 22514272
ICC/IF Use a concentration of 1 µg/ml.
IP Use at an assay dependent concentration. Native.
WB Use at an assay dependent concentration. Detects a band of approximately 92 kDa (predicted molecular weight: 92 kDa). At 1 ug/ml recognizes 10 ng recombinant bacterial, baculo-viral, or native FGFr1.
Flow Cyt 1/100.

Target

  • FunctionReceptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
  • Tissue specificityDetected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
  • Involvement in diseaseDefects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
    Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
    Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
    Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
    Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
  • Cellular localizationMembrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
  • Information by UniProt
  • Database links
  • Alternative names
    • Basic fibroblast growth factor receptor 1 antibody
    • bFGF-R-1 antibody
    • BFGFR antibody
    • CD331 antibody
    • CEK antibody
    • FGFBR antibody
    • FGFR 1 antibody
    • FGFR-1 antibody
    • FGFR1 antibody
    • FGFR1/PLAG1 fusion antibody
    • FGFR1_HUMAN antibody
    • fibroblast growth factor receptor 1 antibody
    • FLG antibody
    • FLT-2 antibody
    • FLT2 antibody
    • Fms-like gene antibody
    • Fms-like tyrosine kinase 2 antibody
    • fms-related tyrosine kinase 2 antibody
    • HBGFR antibody
    • heparin-binding growth factor receptor antibody
    • HH2 antibody
    • HRTFDS antibody
    • hydroxyaryl-protein kinase antibody
    • KAL2 antibody
    • N-SAM antibody
    • OGD antibody
    • Proto-oncogene c-Fgr antibody
    see all

Anti-FGFR1 antibody [M19B2] images

  • ICC/IF image of ab823 stained Hek293 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab823, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • All lanes : Anti-FGFR1 antibody [M19B2] (ab823) at 1 µg/ml

    Lane 1 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
    Lane 2 : MDA-MB-361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Predicted band size : 92 kDa
    Observed band size : 92 kDa
    Additional bands at : 36 kDa,40 kDa,45 kDa,55 kDa. We are unsure as to the identity of these extra bands.
  • Overlay histogram showing MCF7 cells stained with ab823 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab823, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

    Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.
  • Immunofluorescence analysis of rat SV40-VM-NPCs staining FGFR1 with ab823.

    Cells were fixed in paraformaldehyde, permeabilized with 0.3% Triton X-100 and blocked with 5% normal goat serum for 1 hour at room temperature. Cells were incubated with primary antibody (1/1000) overnight at 4°C. An AlexaFluor®568-conjugated anti-mouse IgG (1/200) was used as the secondary antibody.

References for Anti-FGFR1 antibody [M19B2] (ab823)

This product has been referenced in:
  • Lee YW  et al. NGF-induced cell differentiation and gene activation is mediated by integrative nuclear FGFR1 signaling (INFS). PLoS One 8:e68931 (2013). Read more (PubMed: 23874817) »
  • Narla ST  et al. Activation of developmental nuclear fibroblast growth factor receptor 1 signaling and neurogenesis in adult brain by a7 nicotinic receptor agonist. Stem Cells Transl Med 2:776-88 (2013). Read more (PubMed: 24014683) »

See all 7 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 22°C
Antigen retrieval step None
Sample Mouse Tissue sections (Adult brain sections, free floating)
Specification Adult brain sections, free floating
Permeabilization Yes - Triton-X-100 0.1%
Fixative Paraformaldehyde
Username

Mr. Osama Aldalahmah

Verified customer

Submitted Jul 23 2013

Thank you for your enquiry. I am pleased to help answer your questions:

1. I would like to reassure you that both ab108383 and ab6201 are succesfully tested and therefore covered by the Abcam guarantee in ICC-IF. Therefore, any BDNF antibody...

Read More

The specific epitope for this antibody is within amino acids pro146-glu159 of human FGF-R1. ab823 has not yet been tested for reactivity with mouse. I hope this is helpful. Please contact us again if you would like any further information.

Our apologies for giving you incomplete information in the previous inquiry. FGFR1 alpha = 120 kD FGFR1 beta = 105 kD If you have any more questions, please contact us again.

We see a band at approx. 105 kD for "free" FGFR1. When FGFR1 is complexed with FGF, we see a band at approx. 160 kD.

Current lots of these products are in the range of 1.0-1.5 mg/ml.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"